Skylark Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 18-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 18-07-2024
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.50 Cr
as on 18-07-2024
- Revenue -1.81%
(FY 2022)
- Profit 27.08%
(FY 2022)
- Ebitda 940.06%
(FY 2022)
- Net Worth 186.65%
(FY 2022)
- Total Assets 125.08%
(FY 2022)
About Skylark Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹10.50 Cr.
Mukesh Chadderwala, Kamleshkumar Patel, and Prakashbhai Chadderwala serve as directors at the Company.
- CIN/LLPIN
U24230GJ2005PTC046440
- Company No.
046440
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jul 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Skylark Pharmaceuticals Private Limited offer?
Skylark Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Digestive Drugs, Antiemetic Drugs, Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules.
Who are the key members and board of directors at Skylark Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prakashbhai Chadderwala  | Director | 11-Apr-2013 | Current |
| Mukesh Chadderwala | Director | 18-Jul-2005 | Current |
| Kamleshkumar Patel | Director | 18-Jul-2005 | Current |
Financial Performance of Skylark Pharmaceuticals.
Skylark Pharmaceuticals Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 1.81% decrease. The company also saw a substantial improvement in profitability, with a 27.08% increase in profit. The company's net worth Soared by an impressive increase of 186.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skylark Pharmaceuticals?
Unlock access to Skylark Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Neelkanth Lease Finance LimitedActive 35 years 10 monthsMukesh Chadderwala and Prakashbhai Chadderwala are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Oct 2020 | ₹1.00 Cr | Open |
Others Creation Date: 04 Jun 2016 | ₹1.50 Cr | Open |
Prime Co-Operative Bank Limited Creation Date: 19 Feb 2014 | ₹5.50 Cr | Open |
How Many Employees Work at Skylark Pharmaceuticals?
Skylark Pharmaceuticals has a workforce of 10 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skylark Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skylark Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
